Regulation of Ribosome Biogenesis in Hematopoietic Stem Cells
造血干细胞核糖体生物合成的调控
基本信息
- 批准号:10265594
- 负责人:
- 金额:$ 60.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-18 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAllogenicBiochemicalBiogenesisBiologicalBloodBlood CellsBone MarrowBone Marrow TransplantationCell LineCell MaintenanceCell physiologyCellsClinicalClinical TreatmentCollaborationsCytoplasmDataDefectDiseaseEquilibriumEtiologyExhibitsFailureFunctional disorderGene ProteinsGenesGeneticGenetic SuppressionGenomicsGoalsGrowthHematopoiesisHematopoieticHematopoietic stem cellsHumanKnockout MiceLinkMalignant NeoplasmsMarrowMediatingMutationMyeloproliferative diseasePancytopeniaPathway interactionsPatientsPolyribosomesPopulationPredispositionProkaryotic CellsProtein BiosynthesisProteinsProteomicsRegistriesRegulationResearchRibosomal ProteinsRibosomesRoleShwachman-Diamond syndromeSignal TransductionStem cell transplantStructureSyndromeTestingTherapeuticTherapeutic InterventionTranslation Process ProteinTranslationsTransplantationUbiquitinUbiquitinationValidationYeastsbasebone marrow failure syndromecancer predispositioncell growthconditional knockoutepigenomicsexome sequencinggenetic analysisin vivoinsightinterestknock-downnovelnovel therapeutic interventionnovel therapeuticspolypeptidepreventprogramsreconstitutionribosome profilingself-renewalsmall hairpin RNAstem cell functionstem cellstranscriptometranscriptome sequencingtreatment strategyubiquitin-protein ligase
项目摘要
Abstract
Tightly-regulated protein synthesis rates are critical for hematopoietic stem cell (HSC) maintenance and function.
Mutations in ribosome proteins or genes that affect ribosome biogenesis cause “ribosomopathies”, a class of
bone marrow failure (BMF) syndromes. As prominently illustrated by Shwachman-Diamond Syndrome (SDS), a
BMF disease with progressive hematopoietic stem and progenitor cell (HSPC) failure and predisposition to
myeloid malignancies, is driven by germline biallelic mutations in the assembly factors essential for the
maturation of the 60S ribosome subunit. However, how ribosome assembly is regulated in HSCs remains poorly
understood, as is its contribution to hematopoietic dysfunction. Importantly, other than allogeneic stem cell
transplantation, therapeutic interventions that mitigate the HSPC defects in BMF do not exist. This application is
based on our new studies that uncovered a novel role for the E3 ubiquitin ligase, HectD1, in regulating HSC
function via ribosome biogenesis. Hectd1-deficient HSCs exhibit a striking defect in transplantation ability and
self-renewal, concomitant with a reduction in global protein synthesis. The mechanism underlying HSC
dysfunction upon Hectd1 deficiency is directly linked to aberrant ribosome assembly by ubiquitinating and
regulating the stability of ZNF622, a critical biogenesis factor for the maturation of the 60S large ribosomal
subunit in the cytoplasm. Depletion of HectD1 led to an accumulation of ZNF622 and the anti-association factor
eIF6 on the 60S subunit, decreased 80S monosome to 60S ratio, consistent with a subunit joining defect
associated with SDS-like diseases. Importantly, knockdown of ZNF622 in Hectd1-deficient cells restored protein
synthesis and HSC reconstitution capacity. This finding represents a rare in vivo example of genetic suppression
of HSC defects associated with dysfunctional ribosome biogenesis. The implications of this novel pathway to the
etiology of HSC failure and clinical treatment of “ribosomopathies”, mandates detailed mechanistic
understanding. Here, we propose comprehensive and in-depth analyses on the role of HectD1 and ZNF622 in
ribosome biogenesis and HSCs. In aim 1, we propose to investigate the roles of HectD1 and ZNF622 in HSCs
and how they interact to regulate HSC function, using a combination of complementary genetics, genomics, and
biochemical approaches. In aim 2, we will systematically analyze if HectD1/ZNF622 affects different aspects of
protein translation controls. Moreover, we will perform quantitative proteomics to assess if ribosome levels or
ribosome composition is affected by Hectd1/ZNF622 loss. In aim 3, we will interrogate potential dysregulation of
HECTD1 and ZNF622 in human BMF syndromes and explore therapeutic potential of targeting ZNF622 for the
treatment of BMF with dysfunctional ribosome biogenesis. Our study implicates a previously unappreciated role
of ubiquitination in regulating HSC function via controlling ribosome biogenesis factors, which are dysregulated
in ribosomopathies. Our findings will likely have significant impact on the therapeutic potential of modulating
ubiquitination and/or ribosome biogenesis factors in restoring HSC functions in BMF syndromes.
摘要
严格调控的蛋白质合成速率对造血干细胞(HSC)的维持和功能至关重要。
影响核糖体生物发生的核糖体蛋白或基因突变会导致核糖病,这是一类
骨髓衰竭(BMF)综合征。正如Shwachman-Diamond综合征(SDS)所突出说明的那样,
进行性造血干细胞和祖细胞(HSPC)衰竭和易感性的BMF病
髓系恶性肿瘤是由胚系双等位基因突变所致,组装因子对
60S核糖体亚基的成熟。然而,在造血干细胞中核糖体组装是如何被调控的仍然很差。
理解,以及它对造血功能障碍的贡献。重要的是,除了异基因干细胞
移植后,不存在减轻BMF中HSPC缺陷的治疗干预措施。此应用程序是
根据我们的新研究,发现了E3泛素连接酶HectD1在调节HSC中的新作用
通过核糖体生物发生发挥作用。Hectd1缺陷的HSCs在移植能力和
自我更新,伴随着全球蛋白质合成的减少。HSC的潜在机制
Hectd1缺乏症的功能障碍直接与泛素化和核糖体组装异常有关
调控ZNF622的稳定性,ZNF622是60年代大核糖体成熟的关键生物发生因子
细胞质中的亚单位。HectD1的缺失导致ZNF622和抗结合因子的积累
60S亚基上的eIF6降低了80s单体与60s的比率,与亚基连接缺陷一致
与类抑郁疾病有关。重要的是,在Hectd1缺陷细胞中敲除ZNF622恢复了蛋白质
合成和HSC重建能力。这一发现代表了一个罕见的体内基因抑制的例子。
与核糖体生物发生功能障碍相关的HSC缺陷。这一新途径的含义是
HSC衰竭的病因和“核糖体疾病”的临床治疗,要求详细的机制
理解。在这里,我们提出了全面和深入的分析HectD1和ZNF622在
核糖体生物发生与肝干细胞。在目标1中,我们建议研究HectD1和ZNF622在HSCs中的作用
以及它们如何相互作用来调节HSC功能,使用互补遗传学、基因组学和
生化方法。在目标2中,我们将系统分析HectD1/ZNF622是否会影响到
蛋白质翻译控制。此外,我们将进行定量蛋白质组学来评估核糖体水平或
核糖体组成受Hectd1/ZNF622缺失的影响。在目标3中,我们将询问潜在的失调
HECTD1和ZNF622在人BMF综合征中的表达,并探讨靶向ZNF622治疗BMF综合征的可能性
核糖体生物发生功能障碍治疗BMF我们的研究暗示了一个以前未被认识到的角色
泛素化通过调控核糖体生物发生因子调控肝星状细胞功能
在核糖体疾病中。我们的发现可能会对调节药物的治疗潜力产生重大影响。
泛素化和/或核糖体生物发生因子在BMF综合征恢复HSC功能中的作用
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Wei Tong其他文献
Wei Tong的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Wei Tong', 18)}}的其他基金
Novel Regulation of Oncogenic NRAS Signaling in Myeloid Malignancies
髓系恶性肿瘤中致癌 NRAS 信号传导的新调控
- 批准号:
10467363 - 财政年份:2022
- 资助金额:
$ 60.24万 - 项目类别:
Novel Regulation of Oncogenic NRAS Signaling in Myeloid Malignancies
髓系恶性肿瘤中致癌 NRAS 信号传导的新调控
- 批准号:
10580053 - 财政年份:2022
- 资助金额:
$ 60.24万 - 项目类别:
Regulation of Ribosome Biogenesis in Hematopoietic Stem Cells
造血干细胞核糖体生物合成的调控
- 批准号:
10472622 - 财政年份:2020
- 资助金额:
$ 60.24万 - 项目类别:
Regulation of Ribosome Biogenesis in Hematopoietic Stem Cells
造血干细胞核糖体生物合成的调控
- 批准号:
10689326 - 财政年份:2020
- 资助金额:
$ 60.24万 - 项目类别:
Regulation of protein ubiquitination in hematopoietic cytokine signaling
造血细胞因子信号传导中蛋白质泛素化的调节
- 批准号:
9310835 - 财政年份:2017
- 资助金额:
$ 60.24万 - 项目类别:
Clonal Hematopoiesis in Diamond Blackfan Anemia
钻石黑扇贫血症的克隆性造血
- 批准号:
8759862 - 财政年份:2014
- 资助金额:
$ 60.24万 - 项目类别:
Signaling Mechanisms of Different Classes of Thrombopoietin Receptor Agonists
不同类别血小板生成素受体激动剂的信号传导机制
- 批准号:
7875957 - 财政年份:2010
- 资助金额:
$ 60.24万 - 项目类别:
Signaling Mechanisms of Different Classes of Thrombopoietin Receptor Agonists
不同类别血小板生成素受体激动剂的信号传导机制
- 批准号:
8100217 - 财政年份:2010
- 资助金额:
$ 60.24万 - 项目类别:
Lnk Regulatory Functions in Hematopoietic Stem Cells
造血干细胞中的 Lnk 调节功能
- 批准号:
8293214 - 财政年份:2009
- 资助金额:
$ 60.24万 - 项目类别:
相似海外基金
HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
- 批准号:
10039902 - 财政年份:2022
- 资助金额:
$ 60.24万 - 项目类别:
EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
- 批准号:
21K15925 - 财政年份:2021
- 资助金额:
$ 60.24万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
- 批准号:
21K08410 - 财政年份:2021
- 资助金额:
$ 60.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
- 批准号:
20K21672 - 财政年份:2020
- 资助金额:
$ 60.24万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
- 批准号:
18K16395 - 财政年份:2018
- 资助金额:
$ 60.24万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
- 批准号:
17K10951 - 财政年份:2017
- 资助金额:
$ 60.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
- 批准号:
370541 - 财政年份:2017
- 资助金额:
$ 60.24万 - 项目类别:
Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
- 批准号:
16K10863 - 财政年份:2016
- 资助金额:
$ 60.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
- 批准号:
276706135 - 财政年份:2015
- 资助金额:
$ 60.24万 - 项目类别:
Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
- 批准号:
15H04915 - 财政年份:2015
- 资助金额:
$ 60.24万 - 项目类别:
Grant-in-Aid for Scientific Research (B)